Inclusion Criteria
- Participants must have a histologically confirmed diagnosis of a locally advanced
and unresectable or metastatic solid tumor malignancy with a known Kirsten rat
sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).
- Participants must, for Arm D, have a PD-L1 expression (≥50%).
- Participants must have previously received, be ineligible for, or decline (after
having been provided adequate information to make an informed decision) the protocol
defined standard of care (SoC) treatments.
Exclusion Criteria
- Participants must not have untreated central nervous system (CNS) metastases.
- Participants must not have concurrent malignancy (present during screening)
requiring treatment or history of prior malignancy active within 2 years prior to
treatment.
- Participants must not have a history of, or any evidence of, interstitial lung
disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in
the radiation field is permitted.
- Participants must not have a history of prior severe cutaneous adverse reactions
(SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis
(TEN).
- Other protocol-defined Inclusion/Exclusion criteria apply.
